UBX - Unity Biotechnology Inc
IEX Last Trade
1.62
-0.040 -2.469%
Share volume: 29,353
Last Updated: Fri 30 Aug 2024 09:49:38 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$1.66
-0.04
-2.41%
Fundamental analysis
9%
Profitability
8%
Dept financing
6%
Liquidity
50%
Performance
0%
Performance
5 Days
3.82%
1 Month
9.40%
3 Months
4.49%
6 Months
-4.12%
1 Year
-35.57%
2 Year
-66.75%
Key data
Stock price
$1.62
DAY RANGE
N/A - N/A
52 WEEK RANGE
$1.22 - $2.65
52 WEEK CHANGE
-$0.38
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/14/2024
Company detail
CEO: Anirvan Ghosh
Region: US
Website: https://unitybiotechnology.com/
Employees: 46
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: https://unitybiotechnology.com/
Employees: 46
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
unity biotechnology is developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging. unity's initial focus is on creating senolytic medicines to selectively eliminate senescent cells and thereby treat age-related diseases, such as osteoarthritis, eye diseases and pulmonary diseases. more information is available at www.unitybiotechnology.com.
Recent news